Capecitabine, a fluoropyrimidine derivative, is an orally administered drug that delivers 5-fluorouracil (5-FU) selectively to the tumour. The drug has demonstrated activity in metastatic colorectal cancer. We describe a male patient receiving capecitabine therapy with typical chest pain and electrocardiographic changes consistent with ST-segment elevation myocardial infarction. Capecitabine-induced cardiotoxicity may develop in patients who have had a previous episode of 5-FU-induced cardiotoxicity. Capecitabine-induced cardiotoxicity is a rare condition that may lead to diagnostic and therapeutic dilemmas
Fluoropyrimidines, such as capecitabine and 5-fluorouracil, may cause cardiac toxicity. In recent ye...
5-Fluorouracil (5-FU) is a chemotherapeutic agent frequently used for the treatment of solid tumors....
Cardiac toxicity is an uncommon side-effect of 5-fluorouracil (5-FU) treatment, consisting mainly of...
Capecitabine is an orally available fluoropyrimidine carbamate that selectively delivers fluorouraci...
Capecitabine, an oral prodrug of 5-fluorouracil (5-FU), is approved for early-stage and advanced col...
Fluoropyrimidines-5-fluorouracil (5-FU) and capecitabine-have been implicated as cardiotoxic chemoth...
5-Fluorouracil (5-FU) is the most frequently used chemotherapy agent concomitant with radiotherapy i...
Abstract Background 5-Fluorouracil (5-FU) and capecitabine-associated cardiotoxicity ranging from as...
Capecitabine is a chemotherapeutic prodrug that is metabolised to 5-fluorouracil. Supported by the N...
The frequency of capecitabine-related cardiotoxicity has been reported to be low but includes seriou...
Caterina Fontanella,1 Marianna Aita,1 Marika Cinausero,1 Giuseppe Aprile,1 Maria Grazia Baldin,2 Ver...
BACKGROUND: The frequency of capecitabine-related cardiotoxicity has been reported to be low but inc...
Context 5-fluorouracil (5-FU) is an antimetabolite that acts during the S phase of the cell cycle. D...
Background: We aimed to identify the incidence of cardiac events with capecitabine treatment. Method...
Fluoropyrimidines are widely used in cancer therapy for various solid tumours. Cardiotoxicity is an ...
Fluoropyrimidines, such as capecitabine and 5-fluorouracil, may cause cardiac toxicity. In recent ye...
5-Fluorouracil (5-FU) is a chemotherapeutic agent frequently used for the treatment of solid tumors....
Cardiac toxicity is an uncommon side-effect of 5-fluorouracil (5-FU) treatment, consisting mainly of...
Capecitabine is an orally available fluoropyrimidine carbamate that selectively delivers fluorouraci...
Capecitabine, an oral prodrug of 5-fluorouracil (5-FU), is approved for early-stage and advanced col...
Fluoropyrimidines-5-fluorouracil (5-FU) and capecitabine-have been implicated as cardiotoxic chemoth...
5-Fluorouracil (5-FU) is the most frequently used chemotherapy agent concomitant with radiotherapy i...
Abstract Background 5-Fluorouracil (5-FU) and capecitabine-associated cardiotoxicity ranging from as...
Capecitabine is a chemotherapeutic prodrug that is metabolised to 5-fluorouracil. Supported by the N...
The frequency of capecitabine-related cardiotoxicity has been reported to be low but includes seriou...
Caterina Fontanella,1 Marianna Aita,1 Marika Cinausero,1 Giuseppe Aprile,1 Maria Grazia Baldin,2 Ver...
BACKGROUND: The frequency of capecitabine-related cardiotoxicity has been reported to be low but inc...
Context 5-fluorouracil (5-FU) is an antimetabolite that acts during the S phase of the cell cycle. D...
Background: We aimed to identify the incidence of cardiac events with capecitabine treatment. Method...
Fluoropyrimidines are widely used in cancer therapy for various solid tumours. Cardiotoxicity is an ...
Fluoropyrimidines, such as capecitabine and 5-fluorouracil, may cause cardiac toxicity. In recent ye...
5-Fluorouracil (5-FU) is a chemotherapeutic agent frequently used for the treatment of solid tumors....
Cardiac toxicity is an uncommon side-effect of 5-fluorouracil (5-FU) treatment, consisting mainly of...